Bioxytran报告其抗病毒药物ProLectin-M和一种新的中风和脑疾病氧气疗法的进展情况。 Bioxytran reports progress on its antiviral drug ProLectin-M and a new oxygen therapy for stroke and brain diseases.

Bioxytran Inc. Inc. 于2026年1月29日更新了投资者信息, 报告说其主要抗病毒候选者ProLectin-M(ProLectin-M)在完成第二阶段试验和剂量优化后, Bioxytran, Inc. updated investors on January 29, 2026, reporting that its lead antiviral candidate, ProLectin-M, remains under an active U.S. FDA IND application following a completed Phase 2 trial and dose optimization. 该公司正通过与Heme基金会的合资企业,利用经林业发展局核准的设备测量组织氧化情况,推进一个用于中风和神经退化疾病的通用氧气载体。 The company is advancing a universal oxygen carrier for stroke and neurodegenerative diseases via a joint venture with the Heme Foundation, using an FDA-approved device to measure tissue oxygenation. 报告还分享了关于改善癌症免疫疗法的galectin-3调节的临床前研究. It also shared preclinical research on galectin-3 modulation to improve cancer immunotherapy. 更新反映先前披露的情况,并包括有风险的前瞻性说明。 The update reflects prior disclosures and includes forward-looking statements subject to risk.